2179 — Jiangsu Recbio Technology Share News
0.000.00%
Last trade - 00:00- HK$2.38bn
- HK$2.95bn
- CNY12.73m
Brief: Jiangsu Recbio Technology Says New Drug Application For REC610 Shingles Vaccine Accepted By NMPA
Brief: Jiangsu Recbio Technology Says Liu Yong Resigned As Chair
Brief: Jiangsu Recbio Technology Says Li Bu Resigned As Executive Director
Brief: Jiangsu Recbio Technology Says Acceptance By CSRC Of Application Materials For Issuance Of Shares
Brief: Jiangsu Recbio Tech Says Application For Clinical Trial Of Adjuvanted Recombinant HPV 9-Valent Vaccine Accepted
Brief: Jiangsu Recbio Technology To Issue 143.1 Million Domestic Shares
Brief: Jiangsu Recbio Technology Posts HY Loss Attributable RMB247.7 Mln Versus Loss RMB269.1 Mln
Brief: Jiangsu Recbio Technology Posts H1 Capex RMB 78.1 Million
Brief: Jiangsu Recbio Technology Says Liu Yong, Others, Nominated As Executive Director Candidates
Brief: Jiangsu Recbio Technology Posts FY Loss Attributable RMB572.0 Mln
Brief: Spimaco Signs Term Sheet With Jiangsu Recbio Technology On HPV Vaccines
Brief: Jiangsu Recbio Technology Says HY Loss Attributable Rmb272.5 Million
Brief: Jiangsu Recbio Technology Says Acceptance Of Clinical Trial Application
Brief: Jiangsu Recbio Technology Says Got Reply Of Approval From CSRC On Issuance Of Domestic Shares
Brief: Jiangsu Recbio Technology Says Chen Qingqing Was Nominated As Executive Director
Brief: Jiangsu Recbio Technology Posts FY Other Income And Gains Of RMB148 Million
Brief: Jiangsu Recbio Technology Says Component Recombinant Covid-19 Vaccine Got EUA In Mongolia
Brief: Jiangsu Recbio Technology Says It Got Positive Results For A COVID-19 Vaccine Recov Study In Philippines
Brief: Jiangsu Recbio Technology Says It Got Clinical Trial Approval For REC610 In Philippines